{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=61",
    "query": {
      "intervention": "Open Label Extension Study",
      "page": 61
    },
    "page_size": 10
  },
  "pagination": {
    "page": 61,
    "page_size": 10,
    "total_count": 2085,
    "total_pages": 209,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=62&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension+Study&page=60&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T17:08:49.390Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05536297",
      "title": "Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Geographic Atrophy",
        "Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "avacincaptad pegol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 278,
      "start_date": "2022-09-26",
      "completion_date": "2025-04-10",
      "has_results": true,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-11-09T17:08:49.390Z",
      "location_count": 53,
      "location_summary": "Campbell, California • Fresno, California • Fullerton, California + 49 more",
      "locations": [
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05536297"
    },
    {
      "nct_id": "NCT05116046",
      "title": "Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in Achondroplasia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Achondroplasia"
      ],
      "interventions": [
        {
          "name": "Recifercept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Months",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "15 Months to 12 Years"
      },
      "enrollment_count": 35,
      "start_date": "2021-12-24",
      "completion_date": "2023-03-30",
      "has_results": true,
      "last_update_posted_date": "2024-02-08",
      "last_synced_at": "2026-11-09T17:08:49.390Z",
      "location_count": 6,
      "location_summary": "Irvine, California • Long Beach, California • Torrance, California + 2 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05116046"
    },
    {
      "nct_id": "NCT01602120",
      "title": "An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "Lampalizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "60 Years to 89 Years"
      },
      "enrollment_count": 159,
      "start_date": "2012-05-29",
      "completion_date": "2018-02-09",
      "has_results": true,
      "last_update_posted_date": "2019-09-11",
      "last_synced_at": "2026-11-09T17:08:49.390Z",
      "location_count": 41,
      "location_summary": "Tucson, Arizona • Beverly Hills, California • Campbell, California + 37 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01602120"
    },
    {
      "nct_id": "NCT05223920",
      "title": "An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Thrombocythemia, Essential",
        "Primary Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Bomedemstat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 81,
      "start_date": "2021-12-15",
      "completion_date": "2024-08-22",
      "has_results": true,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-11-09T17:08:49.390Z",
      "location_count": 5,
      "location_summary": "Miami, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05223920"
    },
    {
      "nct_id": "NCT01064973",
      "title": "An Open Label Extension Study of STX209 in Subjects With Autism Spectrum Disorders",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorders"
      ],
      "interventions": [
        {
          "name": "arbaclofen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Seaside Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 32,
      "start_date": "2010-02",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2012-12-20",
      "last_synced_at": "2026-11-09T17:08:49.390Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01064973"
    },
    {
      "nct_id": "NCT07623161",
      "title": "A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelofibrosis",
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Elritercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 324,
      "start_date": "2026-09-10",
      "completion_date": "2034-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-09T17:08:49.390Z",
      "location_count": 35,
      "location_summary": "Gilbert, Arizona • Glendale, California • Whittier, California + 27 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07623161"
    },
    {
      "nct_id": "NCT06895070",
      "title": "XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heart Transplant",
        "Heart Failure",
        "Transplant; Failure, Heart"
      ],
      "interventions": [
        {
          "name": "Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "XVIVO Perfusion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2025-07-10",
      "completion_date": "2031-05",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-11-09T17:08:49.390Z",
      "location_count": 14,
      "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06895070"
    },
    {
      "nct_id": "NCT04755283",
      "title": "Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atrial Fibrillation (AF)",
        "Stroke"
      ],
      "interventions": [
        {
          "name": "Abelacimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Anthos Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 1287,
      "start_date": "2021-02-02",
      "completion_date": "2028-12-29",
      "has_results": true,
      "last_update_posted_date": "2025-11-06",
      "last_synced_at": "2026-11-09T17:08:49.390Z",
      "location_count": 28,
      "location_summary": "Huntsville, Alabama • Mobile, Alabama • Stamford, Connecticut + 25 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04755283"
    },
    {
      "nct_id": "NCT03890120",
      "title": "Study of Cilofexor in Adults With Primary Sclerosing Cholangitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Sclerosing Cholangitis"
      ],
      "interventions": [
        {
          "name": "Cilofexor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 419,
      "start_date": "2019-03-27",
      "completion_date": "2022-12-23",
      "has_results": true,
      "last_update_posted_date": "2023-11-29",
      "last_synced_at": "2026-11-09T17:08:49.390Z",
      "location_count": 82,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Coronado, California + 65 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03890120"
    },
    {
      "nct_id": "NCT02032524",
      "title": "Avalglucosidase Alfa Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glycogen Storage Disease Type II Pompe Disease"
      ],
      "interventions": [
        {
          "name": "Avalglucosidase Alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 19,
      "start_date": "2014-02-27",
      "completion_date": "2022-12-12",
      "has_results": true,
      "last_update_posted_date": "2024-03-01",
      "last_synced_at": "2026-11-09T17:08:49.390Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Kansas City, Kansas + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02032524"
    }
  ]
}